The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Eric McDade
Project Title: Proteostasis markers in Alzheimer disease biomarker and clinical progression
Date: June 5, 2025 at 5:19 pm
Request ID: D2523
Aim 1: 1. To explore CSF levels of proteasome related peptides across the AD biomarker progression (Core 1 (-)/Core 2 (-), Core 1 (+)/Core 2 (-), Core 1 (+)/Core 2 (+)).
Aim 2: 2. Evaluate the association of proteasome related peptides with biomarkers of soluble and aggregated forms of amyloid ß and tau, neurodegeneration and microglia.
Aim 3: 3. Assess the ability of UPS vs autophagy-lysosome peptides in predicting longitudinal tau-PET, neurodegeneration and clinical progression.
Aim 4:
Investigator: Philip B. Verghese
Project Title: Establishing Concordance Between the PrecivityAD2™ Blood Test and FDA-Approved CSF Biomarkers to Support Regulatory Submission for AD Diagnosis
Date: June 1, 2025 at 8:31 am
Request ID: D2522
Aim 1: To evaluate the concordance between the PrecivityAD2™ blood test and FDA-cleared Lumipulse CSF β-Amyloid 1-42/1-40 ratio test in individuals with cognitive impairment.
Aim 2:
Aim 3:
Aim 4:
Investigator: Private Funding for Teal Omics
Project Title: Expanding Organ- and Cell-Specific Aging Models to Understand Aging in Health and Diseases
Date: May 28, 2025 at 2:58 pm
Request ID: D2521
Aim 1: Extend aging models to more organs and cell types than initially published
Aim 2: Study how proteome-based organ- and cell-specific aging measures are influenced by health status
Aim 3:
Aim 4:
Investigator: Xiaoping Gu
Project Title: Validation of YWHAG as a Novel Biomarker for Perioperative Neurocognitive Disorders Using Knight-ADRC Plasma Proteomics Data
Date: May 21, 2025 at 11:27 pm
Request ID: D2520
Aim 1: To validate the association between YWHAG protein levels and cognitive impairment using Knight-ADRC plasma proteomic data.
Aim 2: To compare the expression patterns of YWHAG in perioperative cognitive impairment and Alzheimer’s disease cohorts.
Aim 3: To explore the correlation of YWHAG with clinical cognitive scores and other established biomarkers.
Aim 4: To identify potential interacting pathways involving YWHAG that contribute to neurodegeneration.
Investigator: Gabriel Linares
Project Title: Biomarkers for synapse protection in Alzheimer disease
Date: May 13, 2025 at 9:47 am
Request ID: D2519
Aim 1: Evaluate levels of Ryk in biofluids from AD patients to determine if increased Ryk expression correlates with disease severity
Aim 2: Examine the association between Ryk expression and downstream AD pathologies
Aim 3:
Aim 4:
Investigator: Qing Wang
Project Title: Tracking AD Pathology Dynamics Using Multimodal Imaging and Proteomics
Date: May 8, 2025 at 12:07 pm
Request ID: D2518
Aim 1: Characterize the spatiotemporal dynamics among neuroinflammation, amyloid, and tau pathology through integrated imaging and proteomic profiling in AD.
Aim 2: Evaluate the combined effects of neuroinflammation, amyloid, tau, and proteomic markers on cognitive function using ML-based predictive modeling.
Aim 3:
Aim 4:
Investigator: Patrick Luckett
Project Title: Developing a Composite Brain Health Biomarker Using Resting-State fMRI and Multimodal Clinical Data
Date: May 8, 2025 at 8:44 am
Request ID: D2517
Aim 1: Develop a composite brain health score integrating clinical and neurobiological biomarkers.
Aim 2: Train deep learning models to predict the composite brain health score from resting-state functional connectivity
Aim 3: Identify functional connectivity features and brain regions most predictive of the composite score and examine their relationship to clinical measures
Aim 4:
Investigator: Liu Kefu
Project Title: Plasma Proteome-Imaging Biomarker Alliance for Early Alzheimer’s Detection
Date: April 25, 2025 at 5:53 am
Request ID:
Aim 1: 1. Discover Plasma Protein Biomarkers : Analyze proteomic profiles in conjunction with neuroimaging markers (Amyloid/Tau PET SUVR, MRI structural changes) to identify proteins associated with AD progression.
Aim 2: 2. Develop a Multimodal Predictive Model:Combine plasma proteomics, imaging features (e.g., hippocampal volume, cortical thickness), and clinical data using machine learning (LASSO, random forest) to build an AD risk stratification tool.
Aim 3: 3. Elucidate Molecular Mechanisms : Perform bioinformatics analyses (pathway enrichment, protein-protein interaction networks) to uncover links between differential proteins and AD pathology (e.g., neuroinflammation, synaptic dysfunction)
Aim 4:
Investigator: You Cheng
Project Title: Investigating the Role of Tau Pathology and Neuropsychiatric Symptoms in Predicting Conversion to Alzheimer’s Disease in Mild Behavioral Impairment
Date: April 9, 2025 at 10:03 am
Request ID: D2516
Aim 1: Test the Hypothesis: Patients with higher baseline tau levels and MBI will have an increased probability of converting to clinical AD compared to those with lower tau levels.
Aim 2: Investigate Relationships: Examine the relationships among tau pathology, amyloid burden, neuropsychiatric symptoms, cognitive performance, and structural brain changes.
Aim 3: Predictive Modeling: Develop predictive models integrating imaging, genetic, and fluid biomarker data to identify individuals at highest risk for conversion.
Aim 4:
Investigator: Motonobu Fujishima
Project Title: Unraveling Within-Region Temporal Dependencies among Amyloid, Tau, Neurodegeneration, and Cognitive Decline in Alzheimer’s Disease
Date: April 4, 2025 at 8:30 pm
Request ID:
Aim 1: To characterize the within-region temporal sequence among amyloid accumulation, tau deposition, cortical atrophy, and cognitive decline in Alzheimer’s disease, using the OASIS longitudinal AV1451 dataset.
Aim 2: To quantify the degree of temporal coupling and time lag between these outcomes within individual cortical regions.
Aim 3: To assess whether the strength and timing of the progression pathway (Aβ → tau → neurodegeneration → cognition) vary across cortical regions.
Aim 4: